Lyell Immunopharma, Inc. / Fundamentals
Income statement
- Net revenue
€51.48K - Cost of goods sold
€0.00 - Gross profit
€51.48K - SG&A expenses
€43.01M - R&D expenses
€142.83M - EBITDA
-€171.56M - D&A
€13.97M - EBIT
-€305.58M - Interest expenses
€0.00 - EBT
-€284.34M - Tax expenses
€0.00 - Net income
-€284.34M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€109.69M - Changes in working capital
€918.92K - Operating cash flow
-€147.13M - Capex
€443.59K - Other investing cash flow
-€26.89M - Net investing cash flow
€118.01M - Total cash dividends paid
€0.00 - Issuance of common stock
-€827.97K - Debt repayment
€0.00 - Other financing cash flow
€621.19K - Net financing cash flow
€532.82K - Foreign exchange effects
€0.00 - Net change in cash
-€28.59M - Cash at end of period
€86.13M - Free cash flow
-€146.69M
Balance sheet
- Cash and cash equivalents
€84.77M - Cash and short-term investments
€237.49M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€4.65M - Total current assets
€242.14M - Property, plant & equipment
€51.54M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€16.30M - Other non-current assets
€20.74M - Total non-current assets
€88.58M - Total assets
€330.72M - Accounts payable
€2.90M - Short-term debt
€0.00 - Other current liabilities
€28.76M - Total current liabilities
€31.66M - Long-term debt
€39.98M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€2.60M - Total non-current liabilities
€42.58M - Total liabilities
€74.24M - Common stock
€858.00 - Retained earnings
-€1.24B - Other equity
€48.91K - Total equity
€256.48M - Total liabilities and shareholders' equity
€330.72M
Company information
- Market capitalization
€112.92M - Employees
300 - Enterprise Value
€67.87M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -124,498,033,644,435.4% - EBITDA margin
-
-333,255.0% Much better than peer group: -684,573,626,738,166.3% - EBIT margin
-
-593,598.3% Much better than peer group: -690,964,403,778,340.3% - EBT margin
-
-552,328.3% Much better than peer group: -690,144,451,756,014.3% - Net margin
-
-552,328.3% Much better than peer group: -690,144,451,756,009.4% - ROE
-
-110.9% Much worse than peer group: -7.4% - ROA
-
-86.0% Much worse than peer group: -25.8% - Asset turnover
-
0.0% Even with peer group: 3.8% - FCF margin
-
-286,661.7% Much better than peer group: -575,041,400,777,668.5% - FCF yield
-130.7% - Efficiency ratio
333,355.0% - Net sales per employee
-
€171.60 - Net income per employee
-
-€947.80K